300194 福安药业
已收盘 12-26 15:00:00
资讯
新帖
简况
福安药业最新公告：子公司撤回乙酰半胱氨酸注射液药品注册申请
证券之星 · 12-23
福安药业最新公告：子公司撤回乙酰半胱氨酸注射液药品注册申请
福安药业(300194.SZ)子公司撤回乙酰半胱氨酸注射液注册申请
智通财经 · 12-23
福安药业(300194.SZ)子公司撤回乙酰半胱氨酸注射液注册申请
福安药业(300194.SZ)子公司参与全国药品集中采购拟中选
智通财经 · 12-13
福安药业(300194.SZ)子公司参与全国药品集中采购拟中选
福安药业最新公告：子公司部分药品拟中选全国药品集中采购
证券之星 · 12-13
福安药业最新公告：子公司部分药品拟中选全国药品集中采购
福安药业最新公告：子公司收到药品注册证书
证券之星 · 12-05
福安药业最新公告：子公司收到药品注册证书
福安药业(300194.SZ)两款药品收到药品注册证书
智通财经 · 12-05
福安药业(300194.SZ)两款药品收到药品注册证书
福安药业(300194)11月20日股东户数4.22万户，较上期增加4.52%
证券之星 · 11-27
福安药业(300194)11月20日股东户数4.22万户，较上期增加4.52%
福安药业(300194.SZ)：化学原料药头孢托仑匹酯上市申请获得批准
智通财经 · 11-22
福安药业(300194.SZ)：化学原料药头孢托仑匹酯上市申请获得批准
福安药业11月21日现1笔大宗交易 成交金额1175.76万元
新浪证券-红岸工作室 · 11-21
福安药业11月21日现1笔大宗交易 成交金额1175.76万元
11月21日福安药业现1笔溢价13.37%的大宗交易 合计成交1175.76万元
证券之星 · 11-21
11月21日福安药业现1笔溢价13.37%的大宗交易 合计成交1175.76万元
福安药业最新公告：拟投资4.28亿元建设原料药绿色化、智能化高端生产场地建设项目
证券之星 · 11-20
福安药业最新公告：拟投资4.28亿元建设原料药绿色化、智能化高端生产场地建设项目
福安药业(300194.SZ)子公司拟4.28亿元投建原料药绿色化、智能化高端生产场地建设项目
智通财经网 · 11-20
福安药业(300194.SZ)子公司拟4.28亿元投建原料药绿色化、智能化高端生产场地建设项目
福安药业最新公告：子公司博圣制药收到化学原料药上市申请批准通知书
证券之星 · 11-12
福安药业最新公告：子公司博圣制药收到化学原料药上市申请批准通知书
福安药业(300194.SZ)子公司收到苯唑西林钠化学原料药上市申请批准通知书
智通财经 · 11-12
福安药业(300194.SZ)子公司收到苯唑西林钠化学原料药上市申请批准通知书
福安药业最新公告：尼麦角林原料药获得韩国药品注册证书
证券之星 · 11-08
福安药业最新公告：尼麦角林原料药获得韩国药品注册证书
福安药业11月7日现1笔大宗交易 成交金额609.9万元
新浪证券-红岸工作室 · 11-07
福安药业11月7日现1笔大宗交易 成交金额609.9万元
11月7日福安药业现609.9万元大宗交易
证券之星 · 11-07
11月7日福安药业现609.9万元大宗交易
福安药业：TING HE、SHI YUAN ZHU等多人因涉嫌违反证券法律法规等违规行为被证监会责令改正
证券之星 · 11-06
福安药业：TING HE、SHI YUAN ZHU等多人因涉嫌违反证券法律法规等违规行为被证监会责令改正
福安药业：TING HE、WEI GUO CHEN等多人因未依法履行其他职责被深圳证券交易所公开谴责
证券之星 · 11-06
福安药业：TING HE、WEI GUO CHEN等多人因未依法履行其他职责被深圳证券交易所公开谴责
福安药业最新公告：收到对相关承诺方行政监管措施决定书
证券之星 · 11-05
福安药业最新公告：收到对相关承诺方行政监管措施决定书
加载更多
公司概况
公司名称：
福安药业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
2011-03-22
主营业务：
福安药业(集团)股份有限公司主要从事化学药品的研发、生产、销售。主要产品有抗生素类（包括原料药、制剂不同规格）、抗肿瘤类、特色专科药类等药物。
发行价格：
41.88
{"stockData":{"symbol":"300194","market":"SZ","secType":"STK","nameCN":"福安药业","latestPrice":4.53,"timestamp":1735196592000,"preClose":4.54,"halted":0,"volume":15424200,"delay":0,"floatShares":968000000,"shares":1190000000,"eps":0.2368,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.01,"latestTime":"12-26 15:00:00","open":4.52,"high":4.57,"low":4.51,"amount":70077900,"amplitude":0.0132,"askPrice":4.53,"askSize":1078,"bidPrice":4.52,"bidSize":2186,"shortable":0,"etf":0,"ttmEps":0.2368,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735263000000},"adr":0,"adjPreClose":4.54,"symbolType":"stock","openAndCloseTimeList":[[1735176600000,1735183800000],[1735189200000,1735196400000]],"highLimit":4.99,"lowLimit":4.09,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1189712382,"pbRate":1.23,"roa":"--","roe":"7.06%","epsLYR":0.19,"committee":-0.136975,"marketValue":5389000000,"floatMarketCap":4384000000,"peRate":19.130068,"changeRate":-0.0022,"turnoverRate":0.0159,"status":1},"requestUrl":"/m/hq/s/300194","defaultTab":"news","newsList":[{"id":"2493739962","title":"福安药业最新公告：子公司撤回乙酰半胱氨酸注射液药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2493739962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493739962?lang=zh_cn&edition=full","pubTime":"2024-12-23 17:21","pubTimestamp":1734945712,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司庆余堂收到国家药品监督管理局签发的《药品注册申请终止通知书》。根据《药品注册管理办法》第八十九条以及申请人的撤回申请，同意撤回乙酰半胱氨酸注射液的注册申请，终止注册程序。该药品申报的适应症为用于治疗对乙酰氨基酚过量。受市场变化等因素影响，公司决定主动撤回本次注册申请。公司表示，上述研发药品注册申请的主动撤回并终止对公司研发工作无重大影响，预计对公司经营业绩也不会产生重大影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122300023773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0132","BK0060","BK0239","300194"],"gpt_icon":0},{"id":"2493842736","title":"福安药业(300194.SZ)子公司撤回乙酰半胱氨酸注射液注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2493842736","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493842736?lang=zh_cn&edition=full","pubTime":"2024-12-23 16:59","pubTimestamp":1734944354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团庆余堂制药有限公司(简称“庆余堂”)于近日收到国家药品监督管理局签发的《药品注册申请终止通知书》，相关药品为：乙酰半胱氨酸注射液。乙酰半胱氨酸注射液申报的适应症为用于治疗对乙酰氨基酚过量。受市场变化等因素影响，经审慎研究，结合公司研发策略，公司决定主动撤回本次注册申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228410.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0060","BK0239","BK0132","300194"],"gpt_icon":0},{"id":"2491341329","title":"福安药业(300194.SZ)子公司参与全国药品集中采购拟中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2491341329","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491341329?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:17","pubTimestamp":1734081429,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，2024年12月12日，公司全资子公司福安药业集团庆余堂制药有限公司、福安药业集团宁波天衡制药有限公司(简称“庆余堂、天衡制药”)参与了国家组织药品集中采购和使用联合采购办公室(以下简称“联合采购办公室”)组织的第十批全国药品集中采购的投标工作。经联合采购办公室开标、评标后，庆余堂、天衡制药部分药品拟中选本次集中采购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0239","300194","BK0028","BK0060"],"gpt_icon":0},{"id":"2491349420","title":"福安药业最新公告：子公司部分药品拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491349420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491349420?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:11","pubTimestamp":1734081085,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司庆余堂、天衡制药参与了第十批全国药品集中采购的投标工作，部分药品拟中选。庆余堂的注射用氨苄西林钠舒巴坦钠（0.75g）和重酒石酸去甲肾上腺素注射液（1ml∶2mg），天衡制药的盐酸格拉司琼注射液（3ml:3mg）均在拟中选名单中。此外，天衡制药作为受托生产企业与福建海西新药创制股份有限公司合作的药品硫酸羟氯喹片也拟中选。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300029814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0060","300194","BK0239","BK0028"],"gpt_icon":0},{"id":"2489348409","title":"福安药业最新公告：子公司收到药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2489348409","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489348409?lang=zh_cn&edition=full","pubTime":"2024-12-05 16:44","pubTimestamp":1733388275,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司庆余堂、人民制药近日收到国家药品监督管理局签发的药品注册证书。庆余堂的美索巴莫注射液（10ml:1g）和人民制药的注射用氯诺昔康（8mg）通过审批，符合药品注册要求。美索巴莫注射液主要适用于急性骨骼肌疼痛或不适症状的治疗，已有10家企业通过一致性评价。注射用氯诺昔康主要适用于手术后急性中度疼痛的短期治疗，已有14家企业通过一致性评价。上述药品注册证书的获得将丰富子公司产品线，提升市场竞争力，但产品生产、销售情况及对公司业绩的具体影响存在不确定性。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120500027186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0028","BK0132","300194","BK0239"],"gpt_icon":0},{"id":"2489948906","title":"福安药业(300194.SZ)两款药品收到药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2489948906","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489948906?lang=zh_cn&edition=full","pubTime":"2024-12-05 16:15","pubTimestamp":1733386523,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团庆余堂制药有限公司(简称“庆余堂”)、福安药业集团湖北人民制药有限公司(简称“人民制药”)于近日收到国家药品监督管理局签发的药品注册证书，药品名称为美索巴莫注射液、注射用氯诺昔康。据悉，美索巴莫注射液主要适用于急性骨骼肌疼痛或不适症状的治疗。注射用氯诺昔康主要适用于手术后急性中度疼痛的短期治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福安药业(300194.SZ)两款药品收到药品注册证书","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0132","300194","BK0060"],"gpt_icon":0},{"id":"2486848889","title":"福安药业(300194)11月20日股东户数4.22万户，较上期增加4.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486848889","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486848889?lang=zh_cn&edition=full","pubTime":"2024-11-27 17:03","pubTimestamp":1732698234,"startTime":"0","endTime":"0","summary":"证券之星消息，近日福安药业披露，截至2024年11月20日公司股东户数为4.22万户，较11月8日增加1826.0户，增幅为4.52%。在化学制药行业个股中，福安药业股东户数高于行业平均水平，截至11月20日，化学制药行业平均股东户数为3.1万户。从股价来看，2024年11月8日至2024年11月20日，福安药业区间跌幅为2.55%，在此期间股东户数增加1826.0户，增幅为4.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112700027872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0132","300194","BK0060"],"gpt_icon":0},{"id":"2485123882","title":"福安药业(300194.SZ)：化学原料药头孢托仑匹酯上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2485123882","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485123882?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:04","pubTimestamp":1732262647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团重庆博圣制药有限公司(简称“博圣制药”)于近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书(头孢托仑匹酯)。头孢托仑匹酯临床主要用于敏感菌所致的呼吸道、泌尿道、皮肤软组织感染等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0060","BK0239","300194","BK0028"],"gpt_icon":0},{"id":"2485745426","title":"福安药业11月21日现1笔大宗交易 成交金额1175.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485745426","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485745426?lang=zh_cn&edition=full","pubTime":"2024-11-21 17:00","pubTimestamp":1732179600,"startTime":"0","endTime":"0","summary":" 11月21日，福安药业收涨0.80%，收盘价为5.01元，发生1笔大宗交易，合计成交量207万股，成交金额1175.76万元。 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为1785.66万元。该股近5个交易日累计上涨0.40%，主力资金合计净流出4211.94万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-21/doc-incwvitk4609540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0060","300194","BK0132","BK0239"],"gpt_icon":0},{"id":"2485245179","title":"11月21日福安药业现1笔溢价13.37%的大宗交易 合计成交1175.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485245179","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485245179?lang=zh_cn&edition=full","pubTime":"2024-11-21 16:45","pubTimestamp":1732178702,"startTime":"0","endTime":"0","summary":"证券之星消息，11月21日福安药业发生大宗交易，交易数据如下：大宗交易成交价格5.68元，相对当日收盘价溢价13.37%，成交207万股，成交金额1175.76万元，买方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部，卖方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部。截至2024年11月21日收盘，福安药业报收于5.01元，上涨0.8%，换手率3.12%，成交量30.17万手，成交额1.5亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100025934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","300194","BK0132","BK0239"],"gpt_icon":0},{"id":"2484219561","title":"福安药业最新公告：拟投资4.28亿元建设原料药绿色化、智能化高端生产场地建设项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2484219561","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484219561?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:40","pubTimestamp":1732099215,"startTime":"0","endTime":"0","summary":"福安药业公告，公司全资子公司博圣制药拟投资建设“原料药绿色化、智能化高端生产场地建设项目”，项目预计总投资为4.28亿元，以自有资金或银行贷款投资建设。项目建设期预计为两年。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000032159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194","BK0028","BK0239","BK0060","BK0132"],"gpt_icon":0},{"id":"2484981193","title":"福安药业(300194.SZ)子公司拟4.28亿元投建原料药绿色化、智能化高端生产场地建设项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2484981193","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484981193?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:33","pubTimestamp":1732098802,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业 发布公告，公司审议通过了《关于子公司拟投资建设项目的议案》，同意公司全资子公司福安药业集团重庆博圣制药有限公司投资建设“原料药绿色化、智能化高端生产场地建设项目”。该项目的建设主要为满足博圣制药未来发展需要，提高生产能力，适应市场需求，随着近年公司原料药产品注册陆续获批，对博圣制药产能要求逐步加大，着眼于未来发展，拟建设上述项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0060","BK0239","BK0132","300194"],"gpt_icon":0},{"id":"2482962727","title":"福安药业最新公告：子公司博圣制药收到化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482962727","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482962727?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:45","pubTimestamp":1731401158,"startTime":"0","endTime":"0","summary":"福安药业公告，公司全资子公司博圣制药近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书，原料药名称为苯唑西林钠，登记号为Y20230000208，包装规格为5kg/听。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200026726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0132","01477","BK1191","BK0239","300194","BK0028","BK0060"],"gpt_icon":0},{"id":"2482724278","title":"福安药业(300194.SZ)子公司收到苯唑西林钠化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482724278","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482724278?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:30","pubTimestamp":1731400241,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)发布公告，公司全资子公司福安药业集团重庆博圣制药有限公司(简称“博圣制药”)于近日收到国家药品监督管理局签发的苯唑西林钠化学原料药上市申请批准通知书。苯唑西林钠主要用于耐青霉素葡萄球菌所致的各种感染，包括败血症、呼吸道感染、脑膜炎、软组织感染等。也可用于化脓性链球菌或肺炎球菌与耐青霉素葡萄球菌所致的混合感染。上述原料药产品获得上市批准将可以在国内上市制剂中使用，将进一步丰富子公司产品线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0239","BK0028","300194","BK0132"],"gpt_icon":0},{"id":"2481121353","title":"福安药业最新公告：尼麦角林原料药获得韩国药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481121353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481121353?lang=zh_cn&edition=full","pubTime":"2024-11-08 18:20","pubTimestamp":1731061258,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司博圣制药于近日收到韩国食品药品监督管理局原料药品注册证书。尼麦角林适用于急性或慢性脑血管障碍或脑代谢功能不良。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800032419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300194","BK0239","BK0132","BK0060"],"gpt_icon":0},{"id":"2481922273","title":"福安药业11月7日现1笔大宗交易 成交金额609.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481922273","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481922273?lang=zh_cn&edition=full","pubTime":"2024-11-07 17:00","pubTimestamp":1730970000,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 第1笔成交价格为5.35元，成交114.00万股，成交金额609.90万元，溢价率为3.68%，买方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部，卖方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部。 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为609.9万元。该股近5个交易日累计上涨5.95%，主力资金合计净流出660.18万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-07/doc-incvfuhw9012397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","BK0028","BK0132","300194","BK0239"],"gpt_icon":0},{"id":"2481924033","title":"11月7日福安药业现609.9万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2481924033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481924033?lang=zh_cn&edition=full","pubTime":"2024-11-07 16:55","pubTimestamp":1730969742,"startTime":"0","endTime":"0","summary":"证券之星消息，11月7日福安药业发生大宗交易，交易数据如下：大宗交易成交价格5.35元，相对当日收盘价溢价3.68%，成交114万股，成交金额609.9万元，买方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部，卖方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部。截至2024年11月7日收盘，福安药业报收于5.16元，上涨4.45%，换手率7.76%，成交量75.11万手，成交额3.8亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700027902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300194","BK0028","BK0132","BK0239"],"gpt_icon":0},{"id":"2481384696","title":"福安药业：TING HE、SHI YUAN ZHU等多人因涉嫌违反证券法律法规等违规行为被证监会责令改正","url":"https://stock-news.laohu8.com/highlight/detail?id=2481384696","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481384696?lang=zh_cn&edition=full","pubTime":"2024-11-06 01:00","pubTimestamp":1730826039,"startTime":"0","endTime":"0","summary":"证券之星消息，11月5日福安药业公开信息显示，TING HE、SHI YUAN ZHU、WEI GUO CHEN因涉嫌违反证券法律法规,未依法履行其他职责被中国证券监督管理委员会重庆监管局责令改正。处罚决定如下：责令你三人限期改正,在收到本决定之日起180日内,SHI YUAN ZHU应履行回购义务,TING HE和WEI GUO CHEN应承担连带担保责任以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600000489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","161027","BK0239","300194","BK0028","BK0060"],"gpt_icon":0},{"id":"2481263846","title":"福安药业：TING HE、WEI GUO CHEN等多人因未依法履行其他职责被深圳证券交易所公开谴责","url":"https://stock-news.laohu8.com/highlight/detail?id=2481263846","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481263846?lang=zh_cn&edition=full","pubTime":"2024-11-06 01:00","pubTimestamp":1730826034,"startTime":"0","endTime":"0","summary":"证券之星消息，11月5日福安药业公开信息显示，TING HE、WEI GUO CHEN、SHI YUAN ZHU因未依法履行其他职责被深圳证券交易所公开谴责。详细违规行为如下：2019年9月5日,福安药业(集团)股份有限公司与SHIYUANZHU、TINGHE、RedRealtyLLC签署《股权购买和增资协议》,福安药业以7,300万美元取得RedRealtyLLC51%的股权。截至本纪律处分决定书出具之日,SHIYUANZHU、TINGHE和WEIGUOCHEN未按照公开披露的信息履行业绩补偿承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600000487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300194","BK0239","BK0132","BK0060"],"gpt_icon":1},{"id":"2481736535","title":"福安药业最新公告：收到对相关承诺方行政监管措施决定书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481736535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481736535?lang=zh_cn&edition=full","pubTime":"2024-11-05 18:30","pubTimestamp":1730802649,"startTime":"0","endTime":"0","summary":"福安药业公告，公司于2024年11月5日收到中国证券监督管理委员会重庆监管局《关于对SHI YUAN ZHU、TING HE和WEI GUO CHEN采取责令改正行政监管措施的决定》。监管局责令SHI YUAN ZHU在收到决定书之日起180日内履行回购义务，TING HE和WEI GUO CHEN承担连带担保责任。本次监管措施不会影响公司正常经营管理活动。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500031278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300194","BK0028","BK0239","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-03-22","address":"重庆市长寿区化南一路1号","stockEarnings":[{"period":"1week","weight":-0.0483},{"period":"1month","weight":-0.0811},{"period":"3month","weight":0.0837},{"period":"6month","weight":0.2112},{"period":"1year","weight":0.0719},{"period":"ytd","weight":0.0474}],"companyName":"福安药业(集团)股份有限公司","boardCode":"AI0027","perCapita":"23054股","boardName":"医药制造业","registeredCapital":"118971万元","compareEarnings":[{"period":"1week","weight":0.0083},{"period":"1month","weight":0.0424},{"period":"3month","weight":0.1006},{"period":"6month","weight":0.1451},{"period":"1year","weight":0.1659},{"period":"ytd","weight":0.1422}],"survey":" 福安药业(集团)股份有限公司主要从事化学药品的研发、生产、销售。主要产品有抗生素类（包括原料药、制剂不同规格）、抗肿瘤类、特色专科药类等药物。","serverTime":1735252670386,"listedPrice":41.88,"stockholders":"41982人(较上一季度减少0.54%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福安药业,300194,福安药业股票,福安药业股票老虎,福安药业股票老虎国际,福安药业行情,福安药业股票行情,福安药业股价,福安药业股市,福安药业股票价格,福安药业股票交易,福安药业股票购买,福安药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}